Periodic Reporting for period 3 - NeuroDeRisk (Neurotoxicity De-Risking in Preclinical Drug Discovery)

NeuroDeRisk is an “Innovative Medicines Initiative” (IMI2) project aiming to provide novel validated integrated tools for improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system and thus help to de-risk drug candidates earlier in...